BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 20609590)

  • 21. Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.
    Taddei M; Ferrini S; Giannotti L; Corsi M; Manetti F; Giannini G; Vesci L; Milazzo FM; Alloatti D; Guglielmi MB; Castorina M; Cervoni ML; Barbarino M; Foderà R; Carollo V; Pisano C; Armaroli S; Cabri W
    J Med Chem; 2014 Mar; 57(6):2258-74. PubMed ID: 24588105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and anticancer activity of geldanamycin derivatives derived from biosynthetically generated metabolites.
    Lee K; Ryu JS; Jin Y; Kim W; Kaur N; Chung SJ; Jeon YJ; Park JT; Bang JS; Lee HS; Kim TY; Lee JJ; Hong YS
    Org Biomol Chem; 2008 Jan; 6(2):340-8. PubMed ID: 18175003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
    Brough PA; Aherne W; Barril X; Borgognoni J; Boxall K; Cansfield JE; Cheung KM; Collins I; Davies NG; Drysdale MJ; Dymock B; Eccles SA; Finch H; Fink A; Hayes A; Howes R; Hubbard RE; James K; Jordan AM; Lockie A; Martins V; Massey A; Matthews TP; McDonald E; Northfield CJ; Pearl LH; Prodromou C; Ray S; Raynaud FI; Roughley SD; Sharp SY; Surgenor A; Walmsley DL; Webb P; Wood M; Workman P; Wright L
    J Med Chem; 2008 Jan; 51(2):196-218. PubMed ID: 18020435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90.
    Barta TE; Veal JM; Rice JW; Partridge JM; Fadden RP; Ma W; Jenks M; Geng L; Hanson GJ; Huang KH; Barabasz AF; Foley BE; Otto J; Hall SE
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3517-21. PubMed ID: 18511277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and biological activities of azalamellarins.
    Boonya-Udtayan S; Yotapan N; Woo C; Bruns CJ; Ruchirawat S; Thasana N
    Chem Asian J; 2010 Sep; 5(9):2113-23. PubMed ID: 20677319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
    Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
    Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of a novel Hsp90 inhibitor by fragment linking.
    Barker JJ; Barker O; Courtney SM; Gardiner M; Hesterkamp T; Ichihara O; Mather O; Montalbetti CA; Müller A; Varasi M; Whittaker M; Yarnold CJ
    ChemMedChem; 2010 Oct; 5(10):1697-700. PubMed ID: 20665758
    [No Abstract]   [Full Text] [Related]  

  • 28. Domain-mediated dimerization of the Hsp90 cochaperones Harc and Cdc37.
    Roiniotis J; Masendycz P; Ho S; Scholz GM
    Biochemistry; 2005 May; 44(17):6662-9. PubMed ID: 15850399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
    Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
    J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.
    Böll B; Eltaib F; Reiners KS; von Tresckow B; Tawadros S; Simhadri VR; Burrows FJ; Lundgren K; Hansen HP; Engert A; von Strandmann EP
    Clin Cancer Res; 2009 Aug; 15(16):5108-16. PubMed ID: 19671844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells.
    Nakashima T; Ishii T; Tagaya H; Seike T; Nakagawa H; Kanda Y; Akinaga S; Soga S; Shiotsu Y
    Clin Cancer Res; 2010 May; 16(10):2792-802. PubMed ID: 20406843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of new Hsp90 inhibitors by structure-based virtual screening.
    Hong TJ; Park H; Kim YJ; Jeong JH; Hahn JS
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4839-42. PubMed ID: 19560353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.
    He H; Zatorska D; Kim J; Aguirre J; Llauger L; She Y; Wu N; Immormino RM; Gewirth DT; Chiosis G
    J Med Chem; 2006 Jan; 49(1):381-90. PubMed ID: 16392823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and biological evaluation of 3,5-disubstituted-4-alkynylisoxozales as a novel class of HSP90 inhibitors.
    Sun J; Lin C; Qin X; Dong X; Tu Z; Tang F; Chen C; Zhang J
    Bioorg Med Chem Lett; 2015 Aug; 25(16):3129-34. PubMed ID: 26112442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (hsp90).
    Radanyi C; Le Bras G; Messaoudi S; Bouclier C; Peyrat JF; Brion JD; Marsaud V; Renoir JM; Alami M
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2495-8. PubMed ID: 18304811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.
    Cao X; Bloomston M; Zhang T; Frankel WL; Jia G; Wang B; Hall NC; Koch RM; Cheng H; Knopp MV; Sun D
    Clin Cancer Res; 2008 Mar; 14(6):1831-9. PubMed ID: 18347186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin.
    Knox AJ; Price T; Pawlak M; Golfis G; Flood CT; Fayne D; Williams DC; Meegan MJ; Lloyd DG
    J Med Chem; 2009 Apr; 52(8):2177-80. PubMed ID: 19331414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New efficient synthesis of resorcinylic macrolides via ynolides: establishment of cycloproparadicicol as synthetically feasible preclinical anticancer agent based on Hsp90 as the target.
    Yang ZQ; Geng X; Solit D; Pratilas CA; Rosen N; Danishefsky SJ
    J Am Chem Soc; 2004 Jun; 126(25):7881-9. PubMed ID: 15212536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead.
    Meli M; Pennati M; Curto M; Daidone MG; Plescia J; Toba S; Altieri DC; Zaffaroni N; Colombo G
    J Med Chem; 2006 Dec; 49(26):7721-30. PubMed ID: 17181154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Geldanamycin-induced PCNA degradation in isolated Hsp90 complex from cancer cells.
    Wang X; Heuvelman DM; Carroll JA; Dufield DR; Masferrer JL
    Cancer Invest; 2010 Jul; 28(6):635-41. PubMed ID: 20394503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.